IP Library Granted Patent US 8,153,401
Granted Patent B2
US 8,153,401 · App. 11/750,316 · Granted Apr 10, 2012

Method for direct amplification from crude nucleic acid samples

Assignee: Applied Biosystems, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,153,401
App. No.
11/750,316
Granted
Apr 10, 2012
Kind
B2
Abstract

The present teachings relate to improved methods, kits, and reaction mixtures for amplifying nucleic acids. In some embodiments a novel direct buffer formulation is provided which allows for the direct amplification of the nucleic acids in a crude sample with minimal sample purification.

Claims (35)

1. A method of performing a polymerase chain reaction (PCR) comprising;

providing a crude sample comprising deoxyribonucleic acid;

incubating the crude sample with a direct buffer to form a nucleic acid-containing solution; and

performing a polymerase chain reaction (PCR) on said nucleic acid-containing solution, wherein the direct buffer comprises at least 5 PCR primer pairs, Tris-HCl at 10-16 mM, KCl at 50-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 800-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCl2 at 1.6-2.2 mM, and single-stranded binding protein (ssb) of at least 20 ng/ul.

2. The method according to claim 1 , wherein the direct buffer comprises, Tris-HCl at 10 mM pH 8.3, KCl at 50 mM, dNTPs at 200 uM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at 0.16 units/ul, MgCl2 at 1.6 mM, ssb at 60 ng/ul.

3. The method according to claim 2 , wherein the direct buffer further comprises Sodium Azide at 0.02 percent.

4. The method according to claim 2 , wherein the ssb is T4 gene 32 protein from bacteriophage T4.

5. A method of determining the identity of a human comprising:

providing a crude sample comprising deoxyribonucleic acid from the human;

incubating the crude sample with a direct buffer to form a nucleic acid-containing solution, wherein the direct buffer comprises a plurality of primer pairs,

wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR);

wherein the solution comprises the deoxyribonucleic acid from the crude sample;

performing a PCR on the deoxyribonucleic acids from the crude sample to form a plurality of PCR amplicons, wherein each PCR amplicon has an ascertainable size; and,

identifying the human by reference to size of the PCR amplicons, wherein the direct buffer further comprises Tris-HCl at 10-16 mM, KCl at 50-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 800-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCl2 at 1.6-2.2 mM, and ssb of at least 20 ng/ul.

6. The method according to claim 5 , wherein the direct buffer comprises, Tris-HCl at 10 mM pH 8.3, KCl at 50 mM, dNTPs at 200 uM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at 0.16 units/ul, MgCl2 at 1.6 mM, and ssb at 60 ng/ul.

7. The method according to claim 6 , wherein the direct buffer further comprises Sodium Azide at 0.02 percent.

8. The method according to claim 6 wherein the ssb is T4 gene 32 protein from bacteriophage T4.

9. A method of preparing nucleic acids for an enzymatic manipulation comprising:

providing a crude sample comprising deoxyribonucleic acid;

incubating the crude sample with a direct buffer to form a nucleic acid-containing solution;

wherein the solution comprises the deoxyribonucleic acids from the crude sample; and

wherein the direct buffer comprises Tris-HCl at 10-16 mM, KCl at 50-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 800-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCl2 at 1.6-2.2 mM, and ssb of at least 20 ng/ul, and said nucleic acid-containing solution is used in the enzymatic manipulation.

10. The method according to claim 9 wherein the enzymatic manipulation is a PCR.

11. The method according to claim 9 wherein the direct buffer comprises, Tris-HCl at 10 mM pH 8.3, KCl at 50 mM, dNTPs at 200 uM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at 0.16 units/ul, MgCl2 at 1.6 mM, and ssb at 60 ng/ul.

12. The method according to claim 11 wherein the direct buffer further comprises Sodium Azide at 0.02 percent.

13. The method according to claim 11 wherein the ssb is T4 gene 32 protein from bacteriophage T4.

14. A kit for analysis of a crude sample comprising:

a plurality of primer pairs, wherein each primer pair flanks a genomic locus containing a short tandem repeat (STR); and, a direct buffer, wherein the direct buffer comprises Tris-HCl at 10-16 mM, KCl at 50-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 800-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCl2 at 1.6-2.2 mM, and ssb of at least 20 ng/ul.

15. The kit according to claim 14 wherein the direct buffer comprises, Tris-HCl at 10 mM pH 8.3, KCl at 50 mM, dNTPs at 200 uM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at 0.16 units/ul, MgCl2 at 1.6 mM, and ssb at 60 ng/ul.

16. The kit according to claim 15 wherein the direct buffer further comprises Sodium Azide at 0.02 percent.

17. The kit according to claim 15 wherein the ssb is T4 gene 32 protein from bacteriophage T4.

18. A reaction mixture comprising a direct buffer and a plurality of primer pairs, wherein each primer pair flanks a genomic locus of a crude sample containing a short tandem repeat (STR); and wherein the direct buffer comprises Tris-HCl at 10-16 mM, KCl at 50-75 mM, dNTPs at 200-400 uM each dNTP, BSA at 800-960 ug/ml, AmpliTaq Gold polymerase at 2U-8U, MgCl2 at 1.6-2.2 mM, and ssb of at least 20 ng/ul.

19. The reaction mixture according to claim 18 wherein the direct buffer comprises, Tris-HCl at 10 mM pH 8.3, KCl at 50 mM, dNTPs at 200 uM each dNTP, BSA at 800 ug/ml, AmpliTaq Gold polymerase at 0.16 units/ul, MgCl2 at 1.6 mM, and ssb at 60 ng/ul.

20. The reaction according to claim 19 wherein the direct buffer further comprises Sodium Azide at 0.02 percent.

21. The reaction mixture according to claim 19 , wherein the ssb is T4 gene 32 protein from bacteriophage T4.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY NAME PREVIOUSLY RECORDED AT REEL: 030182 FRAME: 0677. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Mar 4, 2016
From: BANK OF AMERICA, N.A.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 038006/0600 →
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: APPLIED BIOSYSTEMS, INC.
Reel/Frame 030182/0677 →
CHANGE OF NAME Recorded Feb 26, 2010
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 023994/0538 →
MERGER Recorded Feb 26, 2010
From: APPLIED BIOSYSTEMS INC.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 023994/0587 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: APPLIED BIOSYSTEMS, LLC
To: BANK OF AMERICA, N.A, AS COLLATERAL AGENT
Reel/Frame 021976/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 7, 2007
From: CHANG, CHIEN-WEI; WANG, DENNIS; HENNESSY, LORI K.
To: APPLERA CORPORATION
Reel/Frame 019799/0519 →
Continuity (1)
Related Publication 20080286772A1 · Nov 20, 2008